How do you pay?

How to pay the least

Ask for the cash price

Yorvipath

We didn’t find one.

  1. Ask your pharmacy for Yorvipath’s cash price, and one or two other pharmacies too.
  2. Yorvipath’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameYorvipath
Authorized genericpalopegteriparatide
Regular genericpalopegteriparatide
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Yorvipath?
The original
–
–

Brand nameThe maker’s card

YORVIPATH Co-Pay Program (A·S·A·P)

Savings card from Ascendis Pharma, Endocrinology

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $5 a month

Sign up on yorvipath.com 

Or call 1-844-442-7236.

In the maker’s words

“Eligible patients with commercial health insurance may pay as little as $5 per month for YORVIPATH…”

From the maker’s offer on yorvipath.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Yorvipath itself, from the same company, sold without the brand name, and usually for less. For now Yorvipath is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

YORVIPATH is a parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults.

Limitations of Use:

  • Not studied for acute post-surgical hypoparathyroidism.
  • Titration scheme only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment.

Source: the FDA label for Yorvipath (Ascendis Pharma, Endocrinology, Inc.), August 12, 2026. Full label on DailyMed 

Good to know